Market research
ADVIC.PA Advicenne S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 20.95
- Dividend yield
- 0.0%
- Beta
- 1.43
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- FR0013296746
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 20.95
- Dividend yield
- 0.0%
- Beta
- 1.43
About
About Advicenne S.A
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ADVIC.PA discussion.
5 years, 4 months ago
Advicenne S.A is currently in a long term downtrend where the price is trading 31.4% below its 200 day moving average.
From a valuation standpoint, the stock is 84.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.8.
Based on the above factors, Advicenne S.A gets an overall score of 1/5.